|
gptkbp:instance_of
|
gptkb:CAR_T-cell_therapy
|
|
gptkbp:advocacy
|
important for awareness
|
|
gptkbp:benefits
|
enhanced immune response
|
|
gptkbp:business_model
|
followed
|
|
gptkbp:clinical_trial
|
gptkb:Athenex,_Inc.
gptkb:United_States
ongoing
Phase 1
Phase 2
multiple phases
analyzed
secured
defined
adaptive design
to be published
potentially significant
|
|
gptkbp:collaboration
|
academic institutions
|
|
gptkbp:collaborations
|
pharmaceutical companies
|
|
gptkbp:developed_by
|
gptkb:Athenex,_Inc.
|
|
gptkbp:dosage_form
|
determined in trials
|
|
gptkbp:duration
|
varies
|
|
gptkbp:eligibility
|
specific criteria
|
|
gptkbp:feedback
|
collected
|
|
gptkbp:funding
|
varied
private investment
|
|
gptkbp:future_prospects
|
expanding indications
|
|
gptkbp:has_research_focus
|
multidisciplinary
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Athenex's T-cell therapy
|
|
gptkbp:investigates
|
identified
|
|
gptkbp:is_monitored_by
|
essential
required during treatment
|
|
gptkbp:is_tested_for
|
under investigation
|
|
gptkbp:mechanism_of_action
|
CAR-T technology
modifies T-cells
|
|
gptkbp:partnerships
|
biotechnology companies
|
|
gptkbp:patient_education
|
provided.
|
|
gptkbp:patient_population
|
adult patients
|
|
gptkbp:provides_guidance_on
|
limited in some areas
|
|
gptkbp:publication
|
peer-reviewed journals
|
|
gptkbp:recruitment
|
critical for success
|
|
gptkbp:regulatory_compliance
|
pending
investigational
|
|
gptkbp:related_products
|
submitted
|
|
gptkbp:research
|
ongoing
|
|
gptkbp:research_areas
|
oncology
|
|
gptkbp:research_focus
|
solid tumors
|
|
gptkbp:research_output
|
promising results
|
|
gptkbp:route_of_administration
|
intravenous
|
|
gptkbp:safety_features
|
under evaluation
|
|
gptkbp:scientific_goals
|
improve outcomes
|
|
gptkbp:side_effect
|
variable
monitored
|
|
gptkbp:targets
|
gptkb:Oncology
|
|
gptkbp:treatment
|
personalized medicine
established
tracked
assessed regularly
addressed in trials
tumor reduction
evaluated in trials
|
|
gptkbp:treatment_innovation
|
continuously evolving
|
|
gptkbp:type
|
gptkb:immunotherapy
|
|
gptkbp:bfsParent
|
gptkb:Athenex
|
|
gptkbp:bfsLayer
|
6
|